Maxigesic approval positive for AFT Pharmaceuticals

Maxigesic approval positive for AFT Pharmaceuticals
AFT founder and managing director Hartley Atkinson. (Image: Supplied)
Tamara Poi-Ngawhika
 AFT Pharmaceuticals, the owner of Maxigesic, offers investors a “large opportunity but with a high degree of uncertainty”, according to Forsyth Barr analysts.The New Zealand stock exchange-listed company has just announced its rapid-release tablet form of Maxigesic has been granted approval by the United States Food and Drug Administration (FDA) for use in the country.Breaking into the US market is difficult because getting FDA approval can be challenging. AFT said the US market is worth about US$7.16 billion (NZ$11.5b) and is...

More Markets

Warehouse drops guidance, loss now in scope
Retail

Warehouse drops guidance, loss now in scope

The retailer has raised the possibility of a full-year earnings loss.

Xero’s Melio ‘leap of faith’
Markets Analysis

Xero’s Melio ‘leap of faith’

The NZ-founded company’s giant-killer dreams in the US hinge on this huge bet. 

NZX ends half year down 3.6%
Markets Market Close

NZX ends half year down 3.6%

"We’ve continued to lag relative to other markets," analyst says.

Gregor Thompson 30 Jun 2025